Skip to main content
Premium Trial:

Request an Annual Quote

Significant, But Not Plausible

You can't trust medical studies -- or at least the statistics, said a panel at the American Association for the Advancement of Science according to Ars Technica. A major issue is the sheer number of data points and the number of tests that researchers are performing. "Even given a low tolerance for error, the sheer number of tests performed ensures that some of them will produce erroneous results at random," the post says. In addition, models can account for the same factor through different mathematical approaches and then spit out completely different results. Members of the panel said that funding agencies and journal editors should lobby for the use of new statistical methods and hold studies to "minimal standard of biological plausibility."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.